Download or read book Direct to consumer Advertising of Prescription Drugs written by United States. Congress. Senate. Special Committee on Aging and published by . This book was released on 2003 with total page 152 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Potential Effects of a Ban on Direct to Consumer Advertising of New Prescription Drugs written by and published by DIANE Publishing. This book was released on with total page 8 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Prescription Drugs written by United States. General Accounting Office and published by . This book was released on 1991 with total page 24 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Prescription Drugs Improvements Needed in FDA s Oversight of Direct to Consumer Advertising written by and published by DIANE Publishing. This book was released on with total page 52 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book The Future of Drug Safety written by Institute of Medicine and published by National Academies Press. This book was released on 2007-02-27 with total page 346 pages. Available in PDF, EPUB and Kindle. Book excerpt: In the wake of publicity and congressional attention to drug safety issues, the Food and Drug Administration (FDA) requested the Institute of Medicine assess the drug safety system. The committee reported that a lack of clear regulatory authority, chronic underfunding, organizational problems, and a scarcity of post-approval data about drugs' risks and benefits have hampered the FDA's ability to evaluate and address the safety of prescription drugs after they have reached the market. Noting that resources and therefore efforts to monitor medications' riskâ€"benefit profiles taper off after approval, The Future of Drug Safety offers a broad set of recommendations to ensure that consideration of safety extends from before product approval through the entire time the product is marketed and used.
Download or read book GAO written by and published by . This book was released on 2003 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Prescription Drug Advertising to Consumers written by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations and published by . This book was released on 1984 with total page 276 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Prescription Drugs Trends in FDA s Oversight of Direct to Consumer Advertising written by Marcia Crosse and published by DIANE Publishing. This book was released on 2008-10 with total page 19 pages. Available in PDF, EPUB and Kindle. Book excerpt: The FDA is responsible for overseeing direct-to-consumer (DTC) advertising (ad) of prescription drugs, which includes TV, magazines, and the Internet. If FDA identifies a violation of laws or reg¿s. in a DTC ad material, the agency may issue a regulatory letter (RL) asking the drug co. to take specific actions. In 2002, there were delays in FDA¿s issuance of these RL. This testimony discusses trends in FDA¿s oversight of DTC ad and the actions FDA has taken when it identifies violations. This statement discusses the: (1) DTC ad materials FDA reviews; (2) FDA¿s process for issuing RL citing DTC ad materials and the number of RL issued; and (3) the effectiveness of FDA¿s RL at limiting the dissemination of false or misleading DTC ad. Charts and tables.
Download or read book From Detached Concern to Empathy written by M.D., Ph.D. Jodi Halpern and published by Oxford University Press. This book was released on 2001-05-10 with total page 188 pages. Available in PDF, EPUB and Kindle. Book excerpt: Physicians recognize the importance of patients' emotions in healing yet believe their own emotional responses represent lapses in objectivity. Patients complain that physicians are too detached. Halpern argues that by empathizing with patients, rather than detaching, physicians can best help them. Yet there is no consistent view of what, precisely, clinical empathy involves. This book challenges the traditional assumption that empathy is either purely intellectual or an expression of sympathy. Sympathy, according to many physicians, involves over-identifying with patients, threatening objectivity and respect for patient autonomy. How can doctors use empathy in diagnosing and treating patients rithout jeopardizing objectivity or projecting their values onto patients? Jodi Halpern, a psychiatrist, medical ethicist and philosopher, develops a groundbreaking account of emotional reasoning as the core of clinical empathy. She argues that empathy cannot be based on detached reasoning because it involves emotional skills, including associating with another person's images and spontaneously following another's mood shifts. Yet she argues that these emotional links need not lead to over-identifying with patients or other lapses in rationality but rather can inform medical judgement in ways that detached reasoning cannot. For reflective physicians and discerning patients, this book provides a road map for cultivating empathy in medical practice. For a more general audience, it addresses a basic human question: how can one person's emotions lead to an understanding of how another person is feeling?
Download or read book Ethical Criteria for Medicinal Drug Promotion written by World Health Organization and published by . This book was released on 1988 with total page 32 pages. Available in PDF, EPUB and Kindle. Book excerpt: "Resolution WHA41.17 adopted by the Forty-first World Health Assembly, 13 May 1988" -- p.1.
Download or read book Making Medicines Affordable written by National Academies of Sciences, Engineering, and Medicine and published by National Academies Press. This book was released on 2018-03-01 with total page 235 pages. Available in PDF, EPUB and Kindle. Book excerpt: Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Download or read book the impact of direct to consumer drug advertising on seniors health and health care costs written by and published by DIANE Publishing. This book was released on with total page 128 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Drugs for Life written by Joseph Dumit and published by Duke University Press. This book was released on 2012-09-03 with total page 277 pages. Available in PDF, EPUB and Kindle. Book excerpt: Challenges our understanding of health, risks, facts, and clinical trials [Payot]
Download or read book Direct to Consumer Advertising of Prescription Drugs written by and published by . This book was released on 2005 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book The Impact of Direct to consumer Drug Advertising on Seniors Health and Health Care Costs written by United States. Congress. Senate. Special Committee on Aging and published by . This book was released on 2006 with total page 128 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Direct to consumer Advertising written by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations and published by . This book was released on 2008 with total page 556 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Reducing Race Differences in Direct to Consumer Pharmaceutical Advertising written by Stephany De Scisciolo and published by Rowman & Littlefield. This book was released on 2018-08-31 with total page 141 pages. Available in PDF, EPUB and Kindle. Book excerpt: Reducing health disparities by increasing access to health information is a national health policy priority. Evidence exists that direct-to-consumer pharmaceutical advertising (DTCA) is effective in educating consumers about health issues. However, racial disparities exist in such advertising. In 2009, the Food and Drug Administration (FDA) issued a report that included recommendations for enhancing the ability of DTCA to reach disadvantaged populations, including racial and ethnic minorities. Reducing Race Differences in Direct to Consumer Pharmaceutical Advertising compares the pharmaceutical advertisements placed in five popular women’s magazines published prior to and following the 2009 FDA report to assess the impact of these recommendations on the content and appearance of advertisements placed in magazines of differing racial orientation. From a health policy perspective, the results are disappointing. The FDA recommendations had no impact on the frequency or content of the DTCA appearing in White-oriented versus Black-oriented magazines. In fact, far fewer drugs used to treat life-threatening conditions were advertised in Black-oriented magazines after the 2009 FDA recommendations. The book concludes that enhancing the educational and motivational value of DTCA will require more than a set of recommendations. The results shed light on the pharmaceutical industry’s compliance with both hard and soft regulation. Neither federal recommendations nor industry guidelines resulted in the changes to DTCA envisioned by the FDA. Regulatory action is necessary to ensure that pharmaceutical companies develop advertising campaigns that not only promote their products, but also positively impact the health outcomes of those who read their ads.
